LASTACAFT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LASTACAFT (LASTACAFT).
Selective histamine H1 receptor antagonist; inhibits mast cell degranulation and reduces release of inflammatory mediators.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine. |
| Excretion | Renal: approximately 70% as unchanged drug; fecal: approximately 30% as metabolites. |
| Half-life | Terminal elimination half-life is approximately 2 hours; clinically, dosing is twice daily. |
| Protein binding | Approximately 60% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is not well defined for ocular administration; systemic Vd is estimated to be 1.4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Ocular: systemic bioavailability is low due to local administration and extensive metabolism; no oral bioavailability data as it is not administered orally. |
| Onset of Action | Ocular: relief of ocular itching occurs within 3 minutes after instillation. |
| Duration of Action | Duration of action is approximately 8-12 hours; recommended dosing every 8-12 hours as needed. |
1 drop in each affected eye twice daily (approximately every 8 hours)
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for any degree of renal impairment. |
| Liver impairment | No dosage adjustment required for any degree of hepatic impairment. |
| Pediatric use | Approved for children 2 years and older: 1 drop in each affected eye twice daily. Safety and efficacy in children under 2 years not established. |
| Geriatric use | No specific dosage adjustment recommended. Use same dose as younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LASTACAFT (LASTACAFT).
| Breastfeeding | It is not known whether alcaftadine is excreted in human milk after ophthalmic administration. Because many drugs are excreted in human milk, caution should be exercised when LASTACAFT is administered to a nursing woman. The M/P ratio is not available. |
| Teratogenic Risk | LASTACAFT (alcaftadine ophthalmic solution) is classified as Pregnancy Category B. Animal studies in rats and rabbits at doses up to 82 and 820 times the maximum recommended human ophthalmic dose (based on systemic AUC) showed no teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, use during pregnancy only if clearly needed. No known fetal risks across trimesters based on limited human data. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component of the formulation"]
| Precautions | ["To minimize contamination, do not touch dropper tip to eyelids or surfaces.","Contact lenses should be removed before instillation and may be reinserted after 10 minutes.","Temporary blurred vision may occur."] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required for ophthalmic use. Systemic exposure is expected to be low after topical ocular administration. Monitor for any systemic adverse effects (e.g., headache, dysgeusia) as per routine clinical practice. |
| Fertility Effects | No fertility studies have been conducted with alcaftadine. Based on its low systemic absorption after ophthalmic dosing, effects on fertility are unlikely. |